What if you could predict placebo responsiveness of each patient in your clinical trial? What if this factor was the difference that reduced data variability and increased study power, so you can get therapies to patients faster? By combining machine learning with patient psychology data – you can.
The placebo response has plagued drug development for decades, causing trial and program failure, increasing development costs and delaying delivery of drugs to patients. Historical strategies to address the placebo response may help but haven't completely solved the placebo response problem.
This is because the quantitative impact of patient psychology on study data has been missing. Until now. In order to fully address the placebo response, unique characteristics of individual patients – like their psychology, perceptions and beliefs – must be considered. But how?
Advanced methods like AI and machine learning are uniquely poised to help scientists uncover the full spectrum of patient placebo responsiveness in a clinical trial. Learn more about this approach by attending our webinar, which explains how a solution like Placebell©™ leverages a time-tested predictive algorithm to improve clinical trial assay sensitivity and de-risk drug development.
Dominique Demolle serves as Chief Executive Officer of Tools4Patient since its inception in 2013. Dr. Demolle holds a Ph.D. in Biochemistry from the University of Brussels. She joined the Clinical Research Group of GD Searle and then Eli Lilly. She has held positions with increasing leadership responsibilities at Eli Lilly and Company with the Lilly Indianapolis Clinical Research Unit in the US and the European Operational Staff management and ultimately became the Associate Director of Global Early Phase Operations. In 2007 she co-founded and successfully developed a Consulting Clinical Research Organization including partnerships with pharma and biotech before she left to set up Tools4Patient with previous colleagues.
Erica Smith joined Tools4Patient as VP of Business Development in 2018. Dr. Smith received a Ph.D. in Biomedical Engineering from The University of Michigan in Ann Arbor.
Dr. Smith began her career in the pharmaceutical industry at Genetics Institute / Wyeth Research in Cambridge, MA and Pfizer in Groton, CT. Dr. Smith then worked for several CROs, developing a strong track record of sales leadership, strategic planning, developing and executing corporate growth strategies and marketing.
Arsalan Arif is a news media entrepreneur who set out in 2015 to build his vision of an independent biotech news company at Endpoints News.